Affordable Access

Publisher Website

Model-based meta-analysis: an important tool for making quantitative decisions during drug development.

Authors
Type
Published Article
Journal
Clinical pharmacology and therapeutics
Publication Date
Volume
92
Issue
3
Pages
283–286
Identifiers
DOI: 10.1038/clpt.2012.122
PMID: 22910485
Source
Medline

Abstract

Modeling during drug development is routinely used to integrate subject-level information, evaluate response, and inform clinical trials. Model-based meta-analysis (MBMA) combines aggregate safety and efficacy results from many trials. Because MBMA is based on results from large numbers of subjects, it increases the power to precisely detect small but clinically significant effects, providing a basis for quantitative drug development decisions and reducing time and cost. This Commentary describes an overview of MBMA and its application during drug development.

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments
F